Soft tissue

General

Grading


Editorial Board Member: Jose G. Mantilla, M.D.
Deputy Editor-in-Chief: Borislav A. Alexiev, M.D.
Farres Obeidin, M.D.

Topic Completed: 14 January 2022

Minor changes: 14 January 2022

Copyright: 2002-2022, PathologyOutlines.com, Inc.

PubMed Search: Soft tissue grading pathology [TI]

Farres Obeidin, M.D.
Page views in 2021: 11,970
Page views in 2022 to date: 435
Cite this page: Obeidin F. Grading. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/softtissuegrading.html. Accessed January 19th, 2022.
Definition / general
  • Grading in soft tissue tumors is to assign a level of differentiation
  • Most important factor in prognosis, metastatic risk and management of soft tissue tumors (Arch Pathol Lab Med 2006;130:1448)
Essential features
  • Grading is required in soft tissue sarcomas where possible
  • Management often relies on the grade
  • FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer) is the most common grading system; defined by a combination of tumor differentiation, mitotic count and necrosis
Terminology
  • FNCLCC: Fédération Nationale des Centres de Lutte Contre le Cancer
  • NCI: National Cancer Institute
  • POG: Pediatric Oncology Group
Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grading
  • Based on a combination of tumor differentiation / histology, mitotic count and tumor necrosis
    • Tumor differentiation
      • Given 1, 2 or 3 points based on how closely it resembles normal tissue
      • See table 1 for specific point values by histologic type
    • Mitotic count: 10 successive high power fields (HPFs) in the most mitotically active area
      • 1 point: 0 - 9 mitoses
      • 2 points: 10 - 19 mitoses
      • 3 points: 20 or more mitoses
    • Tumor necrosis
      • 0 points: no necrosis
      • 1 point: < 50% necrosis
      • 2 points: ≥ 50% necrosis
    • Grade: sum total of tumor differentiation, mitotic count and tumor necrosis scores
      • Grade 1: 2 - 3 points
      • Grade 2: 4 - 5 points
      • Grade 3: 6 - 8 points
  • Additional notes on specific tumors:
    • Sarcomas not graded in the FNCLCC system: embryonal and alveolar rhabdomyosarcoma, angiosarcoma, extraskeletal myxoid chondrosarcoma, alveolar soft part sarcoma, clear cell sarcoma and epithelioid sarcoma
    • Malignant peripheral nerve sheath tumor:
      • FNCLCC grading has been controversial, recent data suggests an overall correlation with survival (Am J Clin Oncol 2022;45:28)
      • Tumor differentiation score may be variable based on closeness to benign peripheral nerve sheath tumors:
        • Score 1: resembles benign peripheral nerve sheath tumor with increased cellularity and mitotic activity
        • Score 2: overtly malignant with characteristics of nerve sheath differentiation (i.e. marbling and short fascicle formation)
        • Score 3: overtly malignant lacking nerve sheath differentiation, having heterologous elements or epithelioid morphology
      • In neurofibromatosis type 1 (NF1) associated tumors, the distinction between neurofibroma and low grade malignant peripheral nerve sheath tumor may be difficult and certain criteria have been proposed (Hum Pathol 2017;67:1) (see table 2)
    • Myxofibrosarcoma grading by FNCLCC is controversial; currently graded by level of cellularity and percentage of myxoid versus solid areas
    • Dedifferentiated liposarcoma:
      • By FNCLCC, well differentiated liposarcoma / atypical lipomatous tumor by definition are grade 1 and dedifferentiated liposarcoma may be grade 2 or 3
      • There remains controversy over whether nonlipogenic areas with low grade features should be classified as low grade dedifferentiation or cellular well differentiated liposarcoma (Am J Surg Pathol 2007;31:1)
      • Well differentiated liposarcoma may represent a spectrum of tumors with variable prognosis (J Surg Oncol 2018;117:1799)
    • Solitary fibrous tumors and gastrointestinal stromal tumors are not graded; metastatic risk is given by specific risk stratification nomograms
  • Grading on core needle biopsies
    • Encouraged where possible but may be limited by amount of tissue
    • Separation at least into low (FNCLCC 1) versus high (FNCLCC 2 and 3) grade is recommended as there are implications for neoadjuvant therapy

Table 1: tumor differentiation score by histologic type
Histologic type
Score
Atypical lipomatous tumor / well differentiated liposarcoma 1
Well differentiated leiomyosarcoma 1
Malignant neurofibroma 1
Well differentiated fibrosarcoma 1
Myxoid liposarcoma 2
Conventional leiomyosarcoma 2
Conventional fibrosarcoma 2
Myxofibrosarcoma 2* (see above)
High grade myxoid liposarcoma 3
Pleomorphic liposarcoma 3
Dedifferentiated liposarcoma 3
Pleomorphic rhabdomyosarcoma 3
Poorly differentiated / pleomorphic leiomyosarcoma 3
Synovial sarcoma 3
Mesenchymal chondrosarcoma 3
Extraskeletal osteosarcoma 3
Extraskeletal Ewing sarcoma 3
Malignant rhabdoid tumor 3
Undifferentiated pleomorphic sarcoma 3
Undifferentiated sarcoma, NOS 3


Table 2: NF1 associated malignant peripheral nerve sheath tumor (MPNST) grading
Grade
Description
Atypical neurofibromatous neoplasm of uncertain biologic potential (ANNUBP) Schwann cell neoplasm with ≥ 2 of 4 features: cytologic atypia, loss of neurofibroma architecture, hypercellularity, < 3 mitoses per 10 HPFs
MPNST, low grade Features of ANNUBP but with mitotic count of 3 - 9 mitoses per 10 HPFs and no necrosis
MPNST, high grade MPNST with ≥ 10 mitoses per 10 HPFs or 3 - 9 mitoses per 10 HPFs combined with necrosis
National Cancer Institute (NCI) grading
  • Less commonly used grading system
  • Similar performance to the FNCLCC grading system but more difficult to objectively quantify (J Clin Oncol 1997;15:350)
  • Uses older terminology and defunct diagnoses

Grade
Tumor type
1
  • Well differentiated liposarcoma
  • Myxoid liposarcoma
  • Subcutaneous myxoid malignant fibrous histiocytoma (defunct)
  • Well differentiated malignant hemangiopericytoma with < 1 mitosis per 10 HPFs, no necrosis and no hemorrhagic areas
  • Well differentiated fibrosarcoma or leiomyosarcoma with no pleomorphism, no necrosis and < 6 mitoses per 10 HPFs
  • Malignant peripheral nerve sheath tumor if resembles neurofibroma with high cellularity and mitotic figures < 6 mitoses per 10 HPFs
  • Myxoid chondrosarcoma that is uniformly myxoid and hypocellular with no mitotic activity
2
  • Other histologic types with < 15% necrosis
3
  • Extraskeletal Ewing sarcoma / primitive neuroectodermal tumor (PNET)
  • Extraskeletal osteosarcoma
  • Mesenchymal chondrosarcoma
  • Malignant triton tumor
  • Other histologic types with ≥ 15% necrosis
Pediatric Oncology Group (POG) grading
  • Created as a modification of the NCI system for use in nonrhabdomyosarcomatous sarcomas in the pediatric population
  • Similar performance to FNCLCC but may upgrade certain tumors (Cancer 2010;116:2266)

Grade
Tumor type
1
  • Myxoid and well differentiated liposarcoma
  • Well differentiated or infantile (≤ 4 years old) fibrosarcoma
  • Well differentiated or infantile (≤ 4 years old) hemangiopericytoma
  • Angiomatoid malignant fibrous histiocytoma (defunct)
  • Deep seated dermatofibrosarcoma protuberans (defunct)
  • Myxoid chondrosarcoma
2
  • < 15% of the surface area shows necrosis
  • Mitotic count is < 5 mitoses per 10 HPFs
  • Nuclear atypia is not marked
  • Tumor is not markedly cellular
3
  • Pleomorphic or round cell liposarcoma
  • Mesenchymal chondrosarcoma
  • Extraskeletal osteogenic sarcoma
  • Malignant triton tumor
  • Alveolar soft part sarcoma
  • Any other sarcoma not in grade 1 with > 15% necrosis or ≥ 5 mitotes per 10 HPFs
Treatment
  • Clinical staging for sarcomas of trunk, extremities and retroperitoneum depends on the grade
    • Localized grade 1 sarcomas are staged as stage IA or IB
    • Grade 2 - 3 sarcomas or metastatic sarcomas are staged as stage II - IV
  • Higher grade tumors often require adjuvant therapy to control their higher metastatic risk
Microscopic (histologic) images

Contributed by Farres Obeidin, M.D.
FNCLCC grade 1

FNCLCC grade 1

FNCLCC grade 3

FNCLCC grade 3

Sample pathology report
  • Right leg, mass, radical resection:
    • Undifferentiated pleomorphic sarcoma, FNCLCC grade 3 (see comment)
    • Comment: Histologic sections demonstrate a pleomorphic malignancy without evidence of definitive line of differentiation, consistent with an undifferentiated pleomorphic sarcoma (score 3). The mitotic count is up to 25 mitoses per 10 HPFs (score 3) and there is necrosis encompassing approximately 20% of the tumor volume (score 1).
Board review style question #1
A 65 year old man presents with a 10 cm leg mass. A core needle biopsy is performed which demonstrates a leiomyosarcoma. Which of the following most accurately describes the factors involved in FNCLCC grading of this lesion?

  1. Mitotic activity, size, necrosis
  2. Pleomorphism, architecture, vascular invasion
  3. Size, age, location
  4. Tumor differentiation, mitotic activity, necrosis
Board review style answer #1
D. FNCLCC grading is based on a combined score of tumor differentiation, mitotic activity and necrosis

Comment Here

Reference: Soft tissue grading
Board review style question #2
A 30 year old woman presents with a 5 cm arm mass. After histologic examination and ancillary studies, a diagnosis of synovial sarcoma is made. The tumor has up to 12 mitoses per 10 HPFs and no necrosis is seen. What is the appropriate FNCLCC grade for this tumor?

  1. FNCLCC grade 1
  2. FNCLCC grade 2
  3. FNCLCC grade 3
  4. Not graded by FNCLCC
Board review style answer #2
B. FNCLCC grade 2. The combination of tumor differentiation (score 3), mitotic activity (score 2) and necrosis (score 0) sum to 5, which falls under grade 2 in the FNCLCC grading system.

Comment Here

Reference: Soft tissue grading
Back to top
Image 01 Image 02